Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada. Reka E Pataky et al. Pharmacoecon Open 2023

https://phgkb.cdc.gov/PHGKB/translationClip.action?action=home